Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity study of Encepur Adults booster vaccination
2017-001356-59Phase 4Completed
- Sponsor
- GSK
- Start
- Aug 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (3 arms), sponsored by GSK. Primary endpoints: Percentage of subjects with detectable TBE neutralizing antibody titres greater than or equal to 2 and Percentage of subjects with detectable TBE neutralizing antibody titres greater than or equal to 10. Started Aug 2017; status: completed.
02
Drugs
tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2017-001356-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001356-59.